SCHEMBL4124861

SCHEMBL4124861

O=C1CCCCC1c1cnc2ccccc2n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.42
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
ALOX15 P16050 2/20 0.42
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
HTT P42858 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
HCAR1 Q9BXC0 2/20 0.37
MCL1 Q07820 1/20 0.36
PTK2 Q05397 1/20 0.36
HSD17B10 Q99714 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
ADORA3 P0DMS8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10445753 0.80 NPC1 (0.47) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL9329013 0.77 SLC6A4 (0.42) NPC1RAB9ASMN1; SMN2ALDH1A1HCAR1
SCHEMBL30853687 0.74 ALDH1A1 (0.60) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL30853698 0.74 ALDH1A1 (0.60) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL1616968 0.74 ALDH1A1 (0.60) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL29184273 0.74 L3MBTL1 (0.45) KDM4ENPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL4129452 0.73 ALDH1A1 (0.59) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL29742364 0.73 ALDH1A1 (0.59) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL29711760 0.73 ALDH1A1 (0.59) KDM4ENPC1RAB9ASMN1; SMN2MAPT
SCHEMBL29742353 0.73 ALDH1A1 (0.59) KDM4ENPC1RAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436005-B2 Macrocyclic pyrimidine derivatives ABBOTT LABORATORIES (US) 2013-05-07 US disclosed
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253678-A1 MACROCYCLIC PYRIMIDINE DERIVATIVES DPYD, TYMS, TYMP KDM4E 3665/4885NPC1 198/4885RAB9A 3371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.